Equity
€114,888 from €213,815 in 2019
Equity fell by 46% in 6 years.
PHARMARIVE
Lifetime
13 annual accounts with figures on one time axispeak €166,358 (2025)
€166,358▲ 11.0%
lowest -€49,435 (2023)
-€19,028▼ €7,516
peak €213,815 (2019)
€114,888▼ 14.2%
€1.7m▲ 1.2%
peak 2.2 FTE (2020)
1.9 FTEunchanged
Board2 names since 2019
1 directorBLUESTONE
Owners
Documentsfilings and deeds
22-08-202622 days late
2025abbreviated format
Loss of €19,028Equity from €133,916 to €114,888Cash from €4,522 to €6,784
Key points
from the 2025 annual accountsLosses
-€79,975 in three years
Every financial year from 2023 to 2025 closed with a loss. 2023 was the heaviest.
Turnover
≈ €780,000 estimated
The accounts state no turnover.
Debts
€1.7m 94% of the balance sheet
Financial debts 9%Suppliers 23%Taxes and wages 2%Other 66%
Of this, €1.5m falls due within a year.
Filings
13 annual accounts since 2013
Ten of the last ten came late. The 2021 accounts came latest: 145 days after the end of the period.
Position in the sector
-€19,028
Lower net result than 85% of companies in retail trade. Sector median €27,442 · 12,842 companies.
Holding: outside the score modelBankruptcy probability: sector outside the model
Checked score
Outside the general model
Holding: general score not applicable
The company has a registered holding activity. Financial fixed assets make up more than half of its assets. The general model for operating companies does not fit such a balance sheet, so there is no score and no financial strength.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
1 signal.
raises risk
raises risk · 2025 accounts filed 22 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-08-2026, 22 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
22 days late
2024
58 days late
2023
92 days late
2022
67 days late
2021
145 days late
2020
89 days late
2019
122 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 85 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 6 October (4 of the last 5 accounts filed within 45 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
1 manager resigning, 1 director reappointed
Resignation: BLUESTONE (manager) · Reappointment: BLUESTONE (director) · Permanent representative: Paul RANSART · General meeting of 29-12-2023 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0521688764
Registered office moved from Woluwe-Saint-Lambert to Etterbeek
New registered office: Rue Gérard 150, 1040 Etterbeek · Previous registered office: Rue de la Rive 49, 1200 Woluwe-Saint-Lambert · Resignation: Hajar Benkhraba (manager) · General meeting of 20-01-2020 · Gazette deed
Incorporation
published on 05-03-2013 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMARIVE Etterbeek | €1.8m | €166,358 | 6.4% | 1.9 |
| APOTHEEK PENDERS Kinrooi | €1.8m | €174,966 | 25.7% | 2.2 |
| PHARMACIE ORBAN Woluwe-Saint-Pierre | €1.5m | €235,324 | 1.4% | 1.9 |
| Leuven Pharma Services Leuven | €2.1m | €190,635 | 16.0% | 2.3 |
| APOTHEEK BOGAERTS KRUISEM Kruisem | €2.0m | €148,747 | -7.3% | 1.3 |
| GEASSOCIEERDE APOTHEEK MARKGRAVE Antwerp | €1.6m | €170,360 | 8.9% | 2.1 |
| KRITO PHARMA Tervuren | €2.0m | €239,878 | 17.8% | 1.6 |
These companies have the same main activity as PHARMARIVE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.5m and €2.1m, founded between 2007 and 2015.
Official details
Source: KBO- Status
- Active since 01-03-2013Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 1 other
- Establishment unit
- 2.217.428.7101950 Kraainem, since 01-03-2013
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Insights on PHARMARIVE
PHARMARIVE files the abbreviated format. That format states no turnover. The gross margin rose from €49,846 in 2013 to €166,358 in 2025.
PALATINE holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMARIVE
- What is the company number of PHARMARIVE?
- The company number of PHARMARIVE is 0521.688.764. The VAT number is the same number with BE in front: BE 0521.688.764.
- Where is PHARMARIVE based?
- The registered office is at Gérardstraat 150, 1040 Etterbeek.Company details
- What does PHARMARIVE do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMARIVE?
- PHARMARIVE is a private limited company (BV).
- When was PHARMARIVE founded?
- PHARMARIVE was founded on 01-03-2013.
- Is PHARMARIVE still active?
- Yes, PHARMARIVE is an active enterprise in the KBO register.
- How many employees does PHARMARIVE have?
- PHARMARIVE had an average of 1.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of PHARMARIVE?
- The turnover in financial year 2025 is ≈ €780,000. This figure is estimated from the gross margin of €166,358 and 51 comparable companies (NACE 477). It probably lies between €520,000 and €1.5m.
- Is PHARMARIVE profitable?
- In financial year 2025, PHARMARIVE made a loss of €19,028.
- Where can I find the annual accounts of PHARMARIVE?
- PHARMARIVE filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMARIVE due?
- PHARMARIVE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See the other companies in the same group.BLUESTONE · 15 companies See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.